Cargando…

Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer

INTRODUCTION: Pembrolizumab cause immune‐related adverse events. We herein report a case of advanced bladder cancer, who treated with pembrolizumab and exhibited intriguing clinical course. CASE PRESENTATION: A 63‐year‐old man with bladder carcinoma was treated by radical cystectomy, however, the bl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Todo, Maki, Kaneko, Gou, Shirotake, Suguru, Shimada, Yuki, Nakano, Shintaro, Okabe, Takashi, Ishikawa, Shiho, Oyama, Masafumi, Nishimoto, Koshiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292166/ https://www.ncbi.nlm.nih.gov/pubmed/32743459 http://dx.doi.org/10.1002/iju5.12128

Ejemplares similares

Editorial Comment to Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer
por: Tomisaki, Ikko
Publicado: (2019)

Delayed nivolumab‐induced hepatotoxicity during pazopanib treatment for metastatic renal cell carcinoma: An autopsy case
por: Todo, Maki, et al.
Publicado: (2019)

Nivolumab-Induced Myasthenia Gravis Concomitant With Myocarditis, Myositis, and Hepatitis
por: Bawek, Sawyer J, et al.
Publicado: (2021)

Pembrolizumab‐induced myasthenia gravis with myositis in a patient with lung cancer
por: Hibino, Makoto, et al.
Publicado: (2018)

Clinical Impact of Consolidative and Salvage Radiotherapy for Lymph Node Metastasis in Upper Urinary Tract Urothelial Carcinoma
por: Kondo, Hideyuki, et al.
Publicado: (2018)

Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report
por: Cham, Jason, et al.
Publicado: (2021)

Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer
por: Huh, So-Young, et al.
Publicado: (2018)

Myocarditis-myositis-myasthenia gravis overlap syndrome depending on immune checkpoint inhibitor
por: Ünlütürk, Zeynep, et al.
Publicado: (2023)

Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma
por: Virgen, Cesar A, et al.
Publicado: (2023)

A case of castration-resistant prostate cancer with liver metastases achieved a complete response by docetaxel chemotherapy
por: Shirotake, Suguru, et al.
Publicado: (2020)

Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib
por: Nishimoto, Koshiro, et al.
Publicado: (2022)

Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis
por: Kufukihara, Kenji, et al.
Publicado: (2019)

Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review
por: Bai, Jing, et al.
Publicado: (2022)

Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report
por: Tian, Chia-Yi, et al.
Publicado: (2021)

Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone
por: Kanao, Kent, et al.
Publicado: (2022)

Anti-Kv1.4 Antibody Without Myasthenia Gravis: A Rare Cause of Autoimmune Myocarditis and Myositis
por: Kuyama, Naoto, et al.
Publicado: (2023)

Pembrolizumab-induced Myasthenia Gravis Relapse after Immunosuppressive Therapy
por: Oshima, Yuki, et al.
Publicado: (2022)

Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single‐center case series
por: Longinow, Joshua, et al.
Publicado: (2022)

Pembrolizumab-Induced Myasthenia Gravis and Myositis: Literature Review on Neurological Toxicities of Programmed Death Protein 1 Inhibitors
por: Schwab, Alfred, et al.
Publicado: (2022)

Thymoma-Associated Myasthenia Gravis With Myocarditis
por: Sarwar, Shihab, et al.
Publicado: (2023)

A Case of Pembrolizumab-Induced Myasthenia Gravis
por: Kosick, Thomas I, et al.
Publicado: (2023)

Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis
por: Fukasawa, Yoko, et al.
Publicado: (2017)

Simultaneous pembrolizumab-induced myasthenia gravis and myocarditis in a patient with metastatic bladder cancer: A case report
por: Takai, Manabu, et al.
Publicado: (2020)

Granulomatous Myositis Associated with Myasthenia Gravis: A Rare Case
por: Iqbal, Shumaila M, et al.
Publicado: (2019)

Presence of Multiple Autoimmune Antibodies Involved in Concurrent Myositis and Myocarditis and Myasthenia Gravis Without Thymoma: A Case Report
por: Zhou, Zhijian, et al.
Publicado: (2019)

Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma
por: Xing, Qian, et al.
Publicado: (2020)

A case in which bladder cancer invaded the ureteral orifice and was resected via photodynamic diagnosis‐assisted transurethral resection involving orally administered 5‐aminolevulinic acid
por: Watanabe, Keitaro, et al.
Publicado: (2019)

A systematic review of myasthenia gravis complicated with myocarditis
por: Cheng, Wei, et al.
Publicado: (2021)

Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: A life–threatening continuum of neuromuscular and cardiac toxicity
por: Rota, Eugenia, et al.
Publicado: (2018)

Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit
por: Deharo, François, et al.
Publicado: (2022)

Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis
por: Ishii, Akiko, et al.
Publicado: (2020)

Pembrolizumab-Induced Myasthenia Gravis and Peripheral Neuropathy: A Case Series
por: McCormack, Sean M, et al.
Publicado: (2023)

Pembrolizumab-Induced Myasthenia Gravis: A Case Report and Review of the Literature
por: Eglenen Polat, Buse, et al.
Publicado: (2023)

Myositis associated to COVID-19 mimics an acute exacerbation in myasthenia gravis patient
por: De Martino, Antonio, et al.
Publicado: (2021)

Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment
por: Luo, Yue-Bei, et al.
Publicado: (2021)

A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil
por: Jespersen, Mette Syberg, et al.
Publicado: (2021)

Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade
por: Nelke, Christopher, et al.
Publicado: (2023)

Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy
por: Onda, Asako, et al.
Publicado: (2019)

Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings—A Case Report and Literature Review
por: Giovannini, Elena, et al.
Publicado: (2023)

Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature
por: Yin, Beibei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e86he4vq2tpbed8n948a6se7vk